Focal distribution of p16/CDKN2 gene mutations within individual prostate carcinomas

International Journal of Oncology

Volumn 8, Issue 3, 1996, Pages 549-554

  Konishi, Noboru ^a   Hiasa, Yoshio ^a   Tao, Ming ^a   Matsuda, Hirofumi ^a   Nakamura, Mitsutoshi ^a   Yane, Katsunari ^a   Kitahori, Yoshiteru ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

p16 CDKN2; Prostate carcinoma; Prostatectomy

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0029972797     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.8.3.549     Document Type: Article

References (35)

1. Pechl DM: Oncogenes in prostate cancer. An update. Cancer 71: 1159-1164, 1993.
2. Konishi N, Emonoto T, Buzard G, Ohshima M, Ward JM, Rice JM: K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 69: 2293-2299, 1992.
3. Konishi N, Hiasa Y, Hayashi I, Matsuda H, Tsuzuki T, Tao M, Kitahori Y, Shiraishi T, Yatani R, Shimazaki J: p53 mutations occur in clinical, but not latent, human prostate carcinoma. Jpn J Cancer Res 86: 57-63, 1995.
4. INK4B gene alterations with immunohistochemical studies in human prostate carcinomas. Int J Oncol 8: 107-112, 1996.
5. Gumerlock PH, Poonamallee UR, Meyers FJ, de Vere White RW: Activated ras allele in human carcinoma of the prostate are rare. Cancer Res 51: 1632-1637, 1991.
6. Uchida T, Wada C, Shitara T, Egawa S, Koshiba K: Infrequent involvement of p53 gene mutations in the tumorigenesis of Japanese prostate cancer. Br J Cancer 68: 751-755, 1993.
7. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369-3373, 1993.
8. Konishi N, Hiasa Y, Matsuda H, Tao M, Tsuzuki T, Hayashi I, Kitahori Y, Shiraishi T, Yatani R, Shimazaki J, Lin J-C: Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol 147: 1112-1122, 1995.
9. Gleason DF: Veterans administration cooperative urological research group, histologic grading and clinical staging of prostate carcinoma. In: Urologic Pathology. The prostate. Tannenbaum M (ed), Philadelphia, Lea & Febiger pp35-46, 1977.
10. Miller GJ, Cygan JM: Morphology of prostate cancer: The effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 152: 1709-1713, 1994.
11. Kamb A, Gruis AG, Weaver-Feldhaus J, Lui Q, Harshman K, Tavtigan SV, Stockert D, Day RS, Johnson BE, Skolnik MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994.
12. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756, 1994.
13. Serrano M, Hannon GJ, Beach DB: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1994.
14. Olopade OI, Bohlander SK, Pomykaka H, Maltepe E, Van Melle E, LeBeau MM, Diaz MO: Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics 14: 431-443, 1992.
15. Peter M, Herskowitz I: Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79: 181-184, 1994.
16. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y: Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54: 3396-3397, 1994.
17. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aiken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8: 22-26, 1994.
18. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo C, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8: 27-32, 1994.
19. Spruck III CH, Gonzalez ZM, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA: p16 gene in uncultured tumors. Nature 370: 183-184, 1994.
20. Zhang SY, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54: 5050-5053, 1994.
21. INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045-11049, 1994.
22. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J: Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 86: 622-625, 1995.
23. Carter BS, Ewing CM, Ward WS, Triger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87: 8751-8755, 1990.
24. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nature Genet 8: 15-21, 1994.
25. Orita M, Iwahara H, Kanazawa H, Hayashi K, Sekiya T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86: 2766-2770, 1989.
26. Diaz MO, Rubin CM, Harden A, Ziemen S, Larson R, Le Beau MM, Rowley JD: Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med 322: 77-82, 1990.
27. James CD, He J, Carlbom E, Nordenskjold M, Cavenee W, Collins VP: Chromosome 9 deletion mapping reveals interferon α and interferon β-1 gene deletions in human glial tumors. Cancer Res 51: 1684-1688, 1991.
28. Cheng JQ, Jhanwar SC, Lu YY, Testa J: Homozygous deletions within chromosome region 9p21-p22 in human malignant mesotheliomas. Cancer Res 53: 4761-4764, 1993.
29. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, Kidd VJ, Housman DE, Dracopoli NC: Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 89: 10557-10561, 1992.
30. Olopade OI, Buchhagen DL, Malik K, Sherman J, Nobori T, Bader S, Nau MM, Gazder AF, Minna JD, Diaz MO: Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 53: 2410-2415, 1993.
31. van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W, Sidransky D: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54: 1156-1158, 1994.
32. Cairns P, Shaw ME, Knowles MA: Initiation of bladder cancer may involve deletion of a tumor suppressor gene on chromosome 9. Oncogene 8: 1083-1085, 1993.
33. Bergerheim USR, Kunimi K, Collins VP, Ekman P: Deletion mapping of chromosome 8, 10 and 16 in human prostatic carcinoma. Genes Chromosom Cancer 3: 215-220, 1991.
34. Moore RA: Morphology of small prostatic carcinomas. J Urol 33: 224, 1935.
35. Harris CC: Clinical and physical carcinogenesis: Advances and perspective for the 1990's. Cancer Res 51: 5023s-5044s, 1991.